Russia Vaccines Market Overview, 2028

Immunization is an essential human right and a vital component of primary healthcare. It's also among the finest investments in health that money can buy. Infectious illness outbreaks can be prevented and controlled with the use of vaccines. They support the security of the world's health and will be a crucial weapon in the fight against antibiotic resistance. Sputnik V, created by the Gamaleya Research Institute of Epidemiology and Microbiology, is the most well-known Russian vaccine. It is a viral vector vaccine that activates an immune response against the SARS-CoV-2 virus using two distinct adenoviruses (Ad26 and Ad5). Sputnik V attracted global attention and was authorized for use in emergency situations in several nations. To administer these vaccines to its populace, the Russian government started immunization campaigns. To accommodate domestic demand, Russian officials have also been seeking to increase these vaccines' production capacity. Through the export of its vaccinations to numerous nations throughout the world, Russia participated in vaccine diplomacy. As part of Russia's efforts to supply vaccines to countries in need, many nations, particularly in Latin America, Asia, and Africa, received supplies of Sputnik V.

According to the research report, “Russia Vaccine Market Overview, 2028” published by Bonafide Research, the market is anticipated to grow with more than 7% CAGR from 2023 to 2028. As the burdens of several diseases are increasing, the use of vaccine has become mandatory for public to maintain a healthy lifestyle. In Russia, the market has seen steady growth in recent years, due to developed healthcare infrastructure, which includes a network of hospitals, clinics, and vaccination centers. This infrastructure allows for efficient vaccine distribution and administration, making it easier for the population to access vaccines. There has been a notable increase in public awareness regarding the importance of vaccination for preventing infectious diseases. This is partly due to public health campaigns and educational initiatives that promote vaccination as a vital tool for individual and community health. Russia actively participates in global vaccine initiatives and collaborations, contributing to the expansion of vaccine access and distribution both domestically and internationally. Along with this, as the elderly population and young children’s are more prone to get infected by the disease therefore, it has increased the intake of vaccines in both age groups, leading to the overall growth of the vaccine market.

The vaccines are produced using different types of technologies, which depend on pathogen which is been targeted. The vaccine produced includes Conjugated vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, and Toxoid vaccines. Live attenuated vaccines are made up of a living virus or bacteria that have been modified through a process to weaken (attenuate) and reduce its virulence (disease-inducing ability). These wild viruses or bacteria are attenuated in a laboratory, usually by repeated culturing. Live attenuated vaccines closely mimic natural infections, stimulating a robust immune response. This often leads to the development of long-lasting immunity. In many cases, a single dose or a few doses are sufficient to provide protection for a significant portion of an individual's life. Live attenuated vaccines are cost-effective because a single dose provides long-lasting protection. This reduces the need for frequent booster shots and associated healthcare costs. The live attenuated vaccine holds significant market share in 2022. The usage of conjugated vaccines in infants has soared due to their effectiveness and safety profile. Infants are particularly vulnerable to infections, and conjugated vaccines provide a reliable means of safeguarding them against diseases like Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, Neisseria meningitidis, and others. These vaccines have revolutionized pediatric healthcare by significantly reducing the incidence of these diseases, thereby preventing countless hospitalizations and saving lives. The high demand for conjugated vaccines in the infant market can be attributed to the increased awareness among parents and healthcare providers about the importance of early immunization, advancements in vaccine technology, and robust vaccination programs implemented by governments and healthcare organizations.

Based on the Route of Administration of vaccine, the market is segmented into Intramuscular and Subcutaneous Administration, Oral Administration, and Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Micro needle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.). Intramuscular and subcutaneous administration of vaccines dominates the market in 2022. This dominance of intramuscular and subcutaneous administration routes in the Russian vaccine market is a reflection of established medical practices and the country's emphasis on vaccination as a crucial component of public health. It also underscores the adaptability of healthcare systems to evolving vaccine technologies and the continued importance of traditional injection methods in ensuring the population's protection against various infectious diseases. The market is further divided into two groups, pediatric vaccines and adult vaccines, according to the end-user of vaccines. The body uses immunity as a means of disease defense. Babies have a higher risk of contracting an infection and developing a serious illness because their immune systems have not fully matured by the time they are born. The use of childhood immunizations is substantially higher than that of adult vaccines. As part of standard immunization schedules, children often receive an extensive series of vaccinations from infancy through puberty. These schedules are carefully created to guard kids against a variety of diseases, such as measles, mumps, rubella, polio, and more. Because of the consistency of the pediatric vaccination schedules, there is a recurrently high demand for these vaccinations. Parental responsibility and understanding are crucial factors in the usage of pediatric vaccines.

Considered in this report:
• Geography: Russia
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028



Aspects covered in this report:
• Russia Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology:
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines

By Route of Administration:
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.)

By End-User:
• Paediatric Vaccines
• Adult Vaccines

By End-User:
• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.)

By Type:
• Multivalent vaccines
• Monovalent vaccines

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Institutional Sales
• Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.